Leslie Trigg Sells 2,120 Shares of Outset Medical (NASDAQ:OM) Stock

Outset Medical, Inc. (NASDAQ:OM) CEO Leslie Trigg sold 2,120 shares of the stock in a transaction on Wednesday, January 21st. The stock was sold at an average price of $5.05, for a total value of $10,706.00. Following the completion of the sale, the chief executive officer owned 105,703 shares in the company, valued at approximately $533,800.15. The trade was a 1.97% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Leslie Trigg also recently made the following trade(s):

• On Tuesday, January 20th, Leslie Trigg sold 11,794 shares of Outset Medical stock. The shares were sold at an average price of $5.12, for a total transaction of $60,385.28.
• On Wednesday, January 7th, Leslie Trigg sold 1,795 shares of Outset Medical stock. The shares were sold at an average price of $4.27, for a total value of $7,664.65.
• On Monday, November 17th, Leslie Trigg sold 916 shares of Outset Medical stock. The shares were sold at an average price of $4.60, for a total transaction of $4,213.60.

Outset Medical Price Performance

Shares of OM traded up $0.15 during mid-day trading on Wednesday, reaching $5.20. The stock had a trading volume of 256,678 shares, compared to its average volume of 1,737,004. Outset Medical, Inc. has a 52-week low of $3.10 and a 52-week high of $21.98. The business’s fifty day moving average is $4.34 and its 200 day moving average is $11.07. The company has a current ratio of 7.09, a quick ratio of 5.77 and a debt-to-equity ratio of 0.69.

Institutional Trading of Outset Medical

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Alyeska Investment Group L.P. lifted its position in shares of Outset Medical by 10.2% in the 3rd quarter. Alyeska Investment Group L.P. now owns 1,614,582 shares of the company’s stock worth $22,798,000 after acquiring an additional 150,000 shares during the period. Assenagon Asset Management S.A. increased its holdings in shares of Outset Medical by 34.8% during the fourth quarter. Assenagon Asset Management S.A. now owns 508,414 shares of the company’s stock worth $1,886,000 after buying an additional 131,381 shares in the last quarter. Pura Vida Investments LLC boosted its stake in Outset Medical by 8,482.4% in the second quarter. Pura Vida Investments LLC now owns 429,120 shares of the company’s stock worth $8,243,000 after purchasing an additional 424,120 shares in the last quarter. Millennium Management LLC increased its position in Outset Medical by 165.8% in the 3rd quarter. Millennium Management LLC now owns 421,409 shares of the company’s stock valued at $5,950,000 after acquiring an additional 262,874 shares in the last quarter. Finally, Geode Capital Management LLC raised its position in shares of Outset Medical by 955.9% during the second quarter. Geode Capital Management LLC now owns 415,552 shares of the company’s stock worth $7,984,000 after acquiring an additional 376,196 shares during the last quarter.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on the stock. Royal Bank Of Canada reaffirmed a “sector perform” rating and issued a $7.00 target price on shares of Outset Medical in a report on Wednesday, December 17th. BTIG Research reissued a “buy” rating and issued a $17.00 target price on shares of Outset Medical in a report on Tuesday, December 16th. Stifel Nicolaus cut their price objective on Outset Medical from $14.00 to $8.00 and set a “buy” rating for the company in a research report on Wednesday, January 7th. Wall Street Zen lowered shares of Outset Medical from a “hold” rating to a “sell” rating in a report on Saturday, January 10th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Outset Medical in a research report on Monday, December 29th. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $10.67.

Outset Medical Company Profile

Outset Medical is a medical technology company specializing in innovations for renal care. The company’s flagship offering, the Tablo Hemodialysis System, is designed to streamline and simplify dialysis treatment across acute and outpatient settings. By integrating water purification, dialysate production, and treatment monitoring into a single device, Tablo aims to reduce the complexity and logistical burden traditionally associated with hemodialysis therapy.

Tablo’s modular design allows for rapid setup and flexible deployment in hospitals, clinics, long‐term care facilities and emergency response scenarios.